Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE102535 | GEO | 2018/05/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.

Project description:Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-approved ruxolitinib) provided limited single-agent responses, possibly due to paradoxical JAK2Y1007/1008 hyperphosphorylation induced by these agents. To determine the importance of mutant JAK2 in B-ALL initiation and maintenance, we developed unique genetically engineered mouse models of B-ALL driven by overexpressed Crlf2 and mutant Jak2, recapitulating the genetic aberrations found in human B-ALL. While expression of mutant Jak2 was necessary for leukemia induction, neither its continued expression nor enzymatic activity was required to maintain leukemia survival and rapid proliferation. CRLF2/JAK2 mutant B-ALLs with sustained depletion or pharmacological inhibition of JAK2 exhibited enhanced expression of c-Myc and prominent up-regulation of c-Myc target genes. Combined indirect targeting of c-Myc using the BET bromodomain inhibitor JQ1 and direct targeting of JAK2 with ruxolitinib potently killed JAK2 mutant B-ALLs.

| S-EPMC6049517 | biostudies-literature

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

Project description:JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

| PRJNA397978 | ENA

Two-Track Epigenetic Remodeling and Backtracking to Embryonic Stem Cell Bivalency in B-cell Acute Lymphoblastic Leukemias

Project description:This SuperSeries is composed of the SubSeries listed below.

2015-02-23 | GSE56602 | GEO

Ph-like acute lymphoblastic leukemia in adults is characterized by IgH-CRFL2 and JAK2 mutations and poor prognosis

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-02-28 | GSE66006 | GEO

Combined targeting of JAK2 and Bcl-xL/Bcl-2 as a novel curative treatment for malignancies expressing mutant JAK2 and overcoming acquired resistance to single agent JAK2 inhibitors

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-09-28 | E-GEOD-51250 | biostudies-arrayexpress

Acute lymphoblastic leukemia

Project description:This SuperSeries is composed of the SubSeries listed below.

2010-09-10 | GSE24001 | GEO

The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Project description:JAK2 plays important roles in the regulation of a variety of cellular processes including cell migration, proliferation, and protection from apoptosis. Recently the L611S point mutation in JAK2 has been identified in a child with acute lymphoblastic leukemia. Here we analyzed the mechanism by which JAK2 exhibits its oncogenicity. In BaF3 murine hematopoietic cells, L611S mutant increased the expression of antiapoptotic proteins including X chromosome-linked inhibitor of apoptosis protein, inhibitor of apoptosis protein, and Bcl-XL. We also showed that JAK2 L611S mutant protects BaF3 cells from cytokine withdrawal-induced apoptotic cell death and leads to cytokine-independent cell growth. Furthermore BaF3 cells expressing JAK2 L611S mutant gained the ability to induce tumorigenesis in nude mice. The L611S mutant also exhibited malignancy, including prompt invasion and spreading into various organs, leading to rapid lethality of the mice. Finally we showed that a specific JAK2 inhibitor, AG490, potently inhibited cytokine-independent cell growth induced by JAK2 L611S mutant via the induction of apoptotic cell death. In addition, treatment with AG490 significantly inhibited the JAK2 L611S mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo strongly suggest that L611S mutant of JAK2 harbors potent oncogenic activity, and this probably requires the antiapoptotic signaling pathway.

| S-EPMC2675997 | biostudies-literature

A transcriptomic continuum of differentiation arrest in acute leukemias

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-12-09 | GSE131207 | GEO

Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-12-02 | E-GEOD-52279 | biostudies-arrayexpress

Genome-wide chromatin maps of T-cell acute lymphoblastic leukemia (T-ALL)

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-03-01 | E-GEOD-54380 | biostudies-arrayexpress